BeiGene to Present Clinical Data on PARP Inhibitor Pamiparib at Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology

CAMBRIDGE, Mass. and BEIJING, China, Nov. 05, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced it will present data on its investigational PARP inhibitor pamiparib at the 23rd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO), being held November 15-18 in New Orleans, LA. Discovered by BeiGene, pamiparib is currently in global clinical development as a monotherapy and in combination with other agents for a variety of solid tumor malignancies.

Oral Presentation: 

Title: Phase 1b/2 study to assess the clinical effects of pamiparib (BGB-290) in combination with radiation therapy (RT) and/or temozolomide (TMZ) in patients with newly diagnosed or recurrent/refractory glioblastoma (GBM)
Presentation #: ACTR-30
Session ID: Concurrent Session 2A: Adult Clinical Trials I/Trials in Development
Location: Grand Ballroom
Date: Friday, November 16
Time: 2:25-2:30 pm CT
Presenter:  Kent Shih, M.D.

About Pamiparib
Pamiparib (BGB-290) is an investigational inhibitor of PARP1 and PARP2 which has demonstrated pharmacological properties such as brain penetration and PARP-DNA complex trapping in preclinical models. Discovered by BeiGene scientists in Beijing, pamiparib is currently in global clinical development as a monotherapy and in combination with other agents for a variety of solid tumor malignancies.

About BeiGene
BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of over 1,700 employees in China, the United States, Australia and Switzerland, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is also working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients. BeiGene markets ABRAXANE® (nanoparticle albumin–bound paclitaxel), REVLIMID® (lenalidomide), and VIDAZA® (azacitidine) in China under a license from Celgene Corporation.1 

Investor Contact
Craig West
+1 857-302-5189
ir@beigene.com

Media Contact
Liza Heapes
+1 857-302-5663 
media@beigene.com

1ABRAXANE®, REVLIMID®, and VIDAZA® are registered trademarks of Celgene Corporation.

Ads

You May Also Like

世界肺癌大會週日記者招待會:推出新獎項和全球指引

日本橫濱, Oct. 17, 2017 (GLOBE NEWSWIRE) -- 國際肺癌研究協會(IASLC)第18届世界肺癌大會(WCLC)的首次新聞簡報會強調鼓勵和支持治療肺癌和其他胸部惡性腫瘤的新獎項和創新,包括嘉獎出色的護理團隊、推出新的護士指引及培養下一代研究人員。 在記者招待會上,首先由大會的聯席主席Hisao Asamura博士和Keunchil Park博士發表歡迎辭,他們為了今年橫濱大會取得圓滿成功作出不懈的努力。 首個癌症護理團隊獎嘉許出色的病人護理 IASLC Foundation將其史上首個癌症護理團隊獎頒發給全球各地的跨學科癌症護理團隊,他們在提供最優質病人護理服務方面超越了外界的期望。該獎項由Matthew ...